SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical stage biotechnology company positioned to lead the development of T cell engagers for autoimmune diseases ...
DAEJEON, South Korea, and HAYWARD, Calif., Oct. 14, 2021 /PRNewswire/ -- IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results